secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aligos Therapeutics, Inc. (ALGS)
CIK:        0001799448
Form:       8-K
Filed at:   2022-03-10T23:59:59+00:00
Accession:  0001171843-22-001773
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic
--------------------------------------------------------------------------------

- Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).
- Cash and investments $205.8M at Dec 31, 2021; sufficient to fund operations into first half 2024.
- CAM (ALG-000184) shows best-in-class HBV DNA/RNA reductions; 12-week studies planned for H2 2022.
- ASO (ALG-020572) Phase 1b in CHB initiated, first cohort enrolled; data expected at a conference in H2 2022.
- Expanded Merck NASH collaboration for second oligonucleotide target; COVID-19 3CL PI candidates more potent than nirmatrelvir.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/0001171843-22-001773-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799448/000117184322001773/f8k_031022.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-001773

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer